Kingmed Diagnostics(SH:603882)2024-04-25 12:17Financial Performance - The company's operating revenue for Q1 2024 was CNY 1,841,260,736.25, representing a decrease of 13.05% compared to the same period last year[4]. - The net profit attributable to shareholders was -CNY 18,637,084.22, a decline of 112.46% year-on-year, primarily due to a high base from the previous year and the traditional off-season in Q1[5]. - The basic and diluted earnings per share were both -CNY 0.04, reflecting a decrease of 112.50% compared to the previous year[5]. - Net profit for Q1 2024 was a loss of ¥26,419,413.39, compared to a profit of ¥140,616,978.25 in Q1 2023, representing a significant decline[21]. - In Q1 2024, the total comprehensive income attributable to the parent company was -18,556,546.62 RMB, compared to 134,742,739.65 RMB in Q1 2023, representing a significant decline[22]. Cash Flow and Liquidity - The net cash flow from operating activities was -CNY 138,310,819.32, down 162.92% year-on-year, attributed to a decrease in business scale and corresponding cash collection[5]. - Cash flow from operating activities in Q1 2024 was -138,310,819.32 RMB, a decrease from 219,822,454.05 RMB in Q1 2023, indicating a negative cash flow trend[25]. - The company reported a significant decrease in cash received from sales and services, totaling 1,547,236,778.10 RMB in Q1 2024, compared to 2,416,436,943.60 RMB in Q1 2023[24]. - The company's cash and cash equivalents decreased, impacting liquidity and operational flexibility[20]. - The ending cash and cash equivalents balance as of the end of Q1 2024 was 2,104,727,955.32 RMB, down from 2,926,679,233.87 RMB at the end of Q1 2023[27]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 11,602,332,636.81, a decrease of 1.41% from the end of the previous year[5]. - The company's total assets decreased to ¥11,602,332,636.81 in Q1 2024 from ¥11,767,672,448.57 in Q1 2023, a reduction of 1.4%[19]. - Total liabilities slightly increased to ¥3,221,414,361.28 in Q1 2024 from ¥3,220,280,284.46 in Q1 2023[19]. - The equity attributable to shareholders decreased by 1.91% to CNY 8,203,286,771.87 compared to the end of the previous year[5]. - The company's equity attributable to shareholders decreased to ¥8,203,286,771.87 in Q1 2024 from ¥8,362,834,963.48 in Q1 2023, reflecting a decline in shareholder value[19]. Operational Efficiency and Strategy - The company is focusing on high-quality development and innovation-driven strategies, enhancing operational efficiency through comprehensive cost management and automation[6]. - New product development is being prioritized, with an emphasis on creating popular products and enhancing customer experience through clinical consultation and product innovation[6]. - The company is exploring new strategies for market expansion and product development to recover from the current financial downturn[20]. - There are no significant new strategies or product developments mentioned in the report for the upcoming quarters[15]. - The company has not disclosed any plans for market expansion or mergers and acquisitions in the near future[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,870, with the top ten shareholders holding significant stakes[11]. - The company has not reported any significant changes in its major shareholders or their participation in margin financing activities[14]. Research and Development - Research and development expenses for Q1 2024 were ¥92,123,715.26, down 30.1% from ¥131,642,934.47 in Q1 2023, indicating a potential shift in focus[21]. Non-Recurring Gains - The company reported non-recurring gains of CNY 10,657,673.84, primarily from government subsidies and asset disposal gains[8].